PRA Health Sciences EBIT

The latest EBIT for PRAH is $300M as of March 2021. That compares with $350M in the prior-year period — down 13.8% year over year. That is below the Healthcare sector average of $99B. Investors often review this figure alongside PRA Health Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, PRAH's EBIT moved from $350M to $300M — a 13.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PRA Health Sciences's operating scale or balance-sheet position.

Against Healthcare companies, PRAH currently prints $300M for EBIT, while the sector average sits near $99B. That is roughly 99.7% below the sector mean. Large gaps often invite a closer look at PRA Health Sciences's growth, margins, and balance sheet.

A EBIT figure of $300M for PRAH is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $99B. Explore the charts below for those layers of context.

After noting PRAH's EBIT ($300M), review year-over-year change from $350M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.